These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2497561)

  • 1. Urinary excretion of valproate and some metabolites in chronically treated patients.
    Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
    Ther Drug Monit; 1989; 11(2):127-33. PubMed ID: 2497561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary metabolites of valproic acid in epileptic patients.
    Katayama H; Watanabe M; Yoshitomi H; Yoshida H; Kimoto H; Kamiya A; Hayashi T; Akimura T
    Biol Pharm Bull; 1998 Mar; 21(3):304-7. PubMed ID: 9556166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite profiles in patients on high-dose valproate monotherapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsy Res; 1996 Oct; 25(2):107-12. PubMed ID: 8884168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy.
    Yoshida H; Hirozane K; Kimoto H; Hayashi T; Akiyama T; Katayama H; Watanabe M; Yoshitomi H; Kamiya A
    Biol Pharm Bull; 1999 Jul; 22(7):716-20. PubMed ID: 10443469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration of metabolites of valproic acid in plasma of epileptic patients.
    Löscher W
    Epilepsia; 1981 Apr; 22(2):169-78. PubMed ID: 6781893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in the renal excretion of valproate and its metabolites after chronic treatment.
    Fisher JE; Nau H; Löscher W
    Epilepsia; 1991; 32(1):146-50. PubMed ID: 1985825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid conjugates: metabolites of 2-propylpentanoic acid (valproic acid) in epileptic patients.
    Gopaul VS; Tang W; Farrell K; Abbott FS
    Drug Metab Dispos; 2003 Jan; 31(1):114-21. PubMed ID: 12485960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid has temporal variability in urinary clearance of metabolites.
    Reith DM; Andrews J; McLaughlin D
    Chronobiol Int; 2001 Jan; 18(1):123-9. PubMed ID: 11247111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of aspirin on valproic acid metabolism.
    Abbott FS; Kassam J; Orr JM; Farrell K
    Clin Pharmacol Ther; 1986 Jul; 40(1):94-100. PubMed ID: 3087680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Lockard JS; Thummel KE; Baillie TA
    Drug Metab Dispos; 1986; 14(4):443-53. PubMed ID: 2873992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of valproate metabolites in children and adolescents.
    Reith DM; Andrews J; Parker-Scott S; Eadie MJ
    Biopharm Drug Dispos; 2000 Nov; 21(8):327-30. PubMed ID: 11514952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
    Murakami K; Sugimoto T; Nishida N; Kobayashi Y; Kuhara T; Matsumoto I
    Brain Dev; 1992 May; 14(3):178-81. PubMed ID: 1514659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA.
    Gopaul S; Farrell K; Abbott F
    Epilepsia; 2003 Mar; 44(3):322-8. PubMed ID: 12614387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspects of the metabolism of valproic acid.
    Granneman GR; Wang SI; Machinist JM; Kesterson JW
    Xenobiotica; 1984 May; 14(5):375-87. PubMed ID: 6433565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep.
    Wong H; Kumar S; Rurak DW; Kwan E; Abbott FS; Riggs KW
    Drug Metab Dispos; 2000 Aug; 28(8):912-9. PubMed ID: 10901700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation and glucuronidation of valproic acid in male rats--influence of phenobarbital, 3-methylcholanthrene, beta-naphthoflavone and clofibrate.
    Heinemeyer G; Nau H; Hildebrandt AG; Roots I
    Biochem Pharmacol; 1985 Jan; 34(1):133-9. PubMed ID: 3917666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.